Skip to main content

Articles

Page 26 of 39

  1. The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-assoc...

    Authors: Yijun Tian, Kongming Wu, Qian Liu, Na Han, Li Zhang, Qian Chu and Yuan Chen
    Citation: Journal of Hematology & Oncology 2016 9:83
    Content type: Research Published on:

  2. Novel immunotherapies, or checkpoint inhibitors, targeting programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have significantly improved outcomes for patients with...

    Authors: Marc Uemura, Van A. Trinh, Cara Haymaker, Natalie Jackson, Dae Won Kim, James P. Allison, Padmanee Sharma, Luis Vence, Chantale Bernatchez, Patrick Hwu and Adi Diab
    Citation: Journal of Hematology & Oncology 2016 9:81
    Content type: Case report Published on:

  3. Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects...

    Authors: Jingjing Wu, Christina Liu, Stella T. Tsui and Delong Liu
    Citation: Journal of Hematology & Oncology 2016 9:80
    Content type: Review Published on:

  4. Optimal post-remission strategy for patients with acute myeloid leukemia (AML) is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but similar survival for allogeneic stem ce...

    Authors: Francesco Saraceni, Myriam Labopin, Norbert-Claude Gorin, Didier Blaise, Reza Tabrizi, Liisa Volin, Jan Cornelissen, Jean-Yves Cahn, Patrice Chevallier, Charles Craddock, Depei Wu, Anne Huynh, William Arcese, Mohamad Mohty and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2016 9:79
    Content type: Research Published on:

  5. Risk stratification based on cytogenetics of acute myeloid leukemia (AML) remains imprecise. The introduction of novel genetic and epigenetic markers has helped to close this gap and increased the specificity ...

    Authors: Stefan Wilop, Wen-Chien Chou, Edgar Jost, Martina Crysandt, Jens Panse, Ming-Kai Chuang, Tim H. Brümmendorf, Wolfgang Wagner, Hwei-Fang Tien and Behzad Kharabi Masouleh
    Citation: Journal of Hematology & Oncology 2016 9:78
    Content type: Research Published on:

  6. Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunologic...

    Authors: Haouraa Mostafa, Andrej Pala, Josef Högel, Michal Hlavac, Elvira Dietrich, M. Andrew Westhoff, Lisa Nonnenmacher, Timo Burster, Michael Georgieff, C. Rainer Wirtz and E. Marion Schneider
    Citation: Journal of Hematology & Oncology 2016 9:77
    Content type: Research Published on:

  7. Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy against HER2-positive gastric cancer. However, recurrent therapeutic resistance presents revolutionary claims. Warburg...

    Authors: Jing Liu, Changqie Pan, Lihong Guo, Mengwan Wu, Jing Guo, Sheng Peng, Qianying Wu and Qiang Zuo
    Citation: Journal of Hematology & Oncology 2016 9:76
    Content type: Research Published on:

  8. Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant plasma cells in a hypoxic bone marrow environment. Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR) sig...

    Authors: Thea Kristin Våtsveen, Anne-Marit Sponaas, Erming Tian, Qing Zhang, Kristine Misund, Anders Sundan, Magne Børset, Anders Waage and Gaute Brede
    Citation: Journal of Hematology & Oncology 2016 9:75
    Content type: Research Published on:

  9. Hepatocellular carcinoma (HCC) remains one of the most common and lethal malignancies worldwide despite the development of various therapeutic strategies. A better understanding of the mechanisms responsible f...

    Authors: Aparna Jayachandran, Bijay Dhungel and Jason C. Steel
    Citation: Journal of Hematology & Oncology 2016 9:74
    Content type: Review Published on:

  10. Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomo...

    Authors: Joel G. Turner, Jana L. Dawson, Steven Grant, Kenneth H. Shain, William S. Dalton, Yun Dai, Mark Meads, Rachid Baz, Michael Kauffman, Sharon Shacham and Daniel M. Sullivan
    Citation: Journal of Hematology & Oncology 2016 9:73
    Content type: Research Published on:

  11. We demonstrate the synergistic antitumor effect of oridonin and the PI3K/mTOR inhibitor NVP-BEZ235 on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) both in vitro ...

    Authors: Kai Qing, Zhen Jin, Wanbin Fu, Wenfang Wang, Zhao Liu, Xiaoyang Li, Zizhen Xu and Junmin Li
    Citation: Journal of Hematology & Oncology 2016 9:72
    Content type: Letter to the Editor Published on:

  12. The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoi...

    Authors: Michael M. B. Green, Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, Jagadish Kummetha Venkata, Gwynn Long, Alice Mims, David Rizzieri, Stefanie Sarantopoulos, Robert Stuart, Anthony D. Sung, Keith M. Sullivan, Luciano Costa…
    Citation: Journal of Hematology & Oncology 2016 9:71
    Content type: Research Published on:

  13. Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundr...

    Authors: Yongxian Hu, Jie Sun, Zhao Wu, Jian Yu, Qu Cui, Chengfei Pu, Bin Liang, Yi Luo, Jimin Shi, Aiyun Jin, Lei Xiao and He Huang
    Citation: Journal of Hematology & Oncology 2016 9:70
    Content type: Letter to the Editor Published on:

  14. Abnormal expression of SOCS3 has been implicated in myeloproliferative neoplasms, but the role of SOCS3 in the pathogenesis of leukemia remains largely unknown. Here, we examined the function of SOCS3 in the g...

    Authors: Yu-xiao Liu, Li Wang, Wen-jia Liu, Hai-tao Zhang, Jing-hui Xue, Zhi-wen Zhang and Chun-ji Gao
    Citation: Journal of Hematology & Oncology 2016 9:69
    Content type: Research Published on:

  15. The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance frequently develops. Alternative agents that can overcome drug resistance would offer new therapeutic optio...

    Authors: Pin Zhang, Zhongsheng Tong, Fuguo Tian, Yongsheng Wang, Junlan Yang, Weilian Li, Lijun Di, Wei Liu, Li Tang, Rongguo Qiu and Binghe Xu
    Citation: Journal of Hematology & Oncology 2016 9:68
    Content type: Research Published on:

  16. Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication. Standard tre...

    Authors: Enrico Maffini, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Ilaria Buondonno, Dario Ferrero, Mario Boccadoro, Chiara Dellacasa, Alessandro Busca, Domenico Novero and Benedetto Bruno
    Citation: Journal of Hematology & Oncology 2016 9:67
    Content type: Case report Published on:

  17. Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic driv...

    Authors: Fei-fei Gu, Yong Zhang, Yang-yang Liu, Xiao-hua Hong, Jin-yan Liang, Fan Tong, Jing-song Yang and Li Liu
    Citation: Journal of Hematology & Oncology 2016 9:66
    Content type: Letter to the Editor Published on:

  18. Data comparing fully matched and mismatched-unrelated-donor (M- and mM-URD) allogeneic hematopoietic stem cell transplant (allo-SCT) following reduced intensity conditioning regimens for acute myeloid leukemia...

    Authors: Marie T. Rubio, Bipin N. Savani, Myriam Labopin, Emmanuelle Polge, Dietger Niederwieser, Arnold Ganser, Rainer Schwerdtfeger, Gerhard Ehninger, Jürgen Finke, Arnold Renate, Charles Craddock, Nicolaus Kröger, Michael Hallek, Pavel Jindra, Mohamad Mohty and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2016 9:65
    Content type: Research Published on:

  19. The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for ...

    Authors: Hasan Mahmud, Steven M. Kornblau, Arja ter Elst, Frank J. G. Scherpen, Yi Hua Qiu, Kevin R. Coombes and Eveline S. J. M. de Bont
    Citation: Journal of Hematology & Oncology 2016 9:64
    Content type: Letter to the Editor Published on:

  20. We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR ...

    Authors: Giovanni Caocci, Marianna Greco, Giuseppe Delogu, Christian Secchi, Bruno Martino, Claudia Labate, Elisabetta Abruzzese, Malgorzata Monika Trawinska, Sara Galimberti, Federica Orru, Claudio Fozza, Carlo Gambacorti Passerini, Francesco Galimi and Giorgio La Nasa
    Citation: Journal of Hematology & Oncology 2016 9:63
    Content type: Letter to the Editor Published on:

  21. Telomere erosion can lead to genomic instability and cancer progression. It has been suggested that the shortest telomere, not the average telomere length (TL), is critical for cell viability. Some studies hav...

    Authors: Sang Mee Hwang, Seon Young Kim, Jung Ah Kim, Hee-Sue Park, Si Nae Park, Kyongok Im, Kwantae Kim, Sung-Min Kim and Dong Soon Lee
    Citation: Journal of Hematology & Oncology 2016 9:62
    Content type: Research Published on:

  23. Venous thromboembolism (VTE) is a well-recognised and life-threatening complication in patients with cancer. However, the precise risk of VTE in hospitalised cancer patients in England has not been previously ...

    Authors: Sonia Ratib, Alex J. Walker, Tim R. Card and Matthew J. Grainge
    Citation: Journal of Hematology & Oncology 2016 9:60
    Content type: Research Published on:

  24. T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant select...

    Authors: Shuhang Wang, Stella T. Tsui, Christina Liu, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2016 9:59
    Content type: Review Published on:

  26. Recent evidence indicates that long noncoding RNAs (lncRNAs) play pivotal roles in the regulation of cellular processes and are found to be dysregulated in a variety of cancers. LINC00261 is an lncRNA that is ...

    Authors: Yu Fan, Yan-fen Wang, Hua-fang Su, Na Fang, Chen Zou, Wen-feng Li and Zheng-hua Fei
    Citation: Journal of Hematology & Oncology 2016 9:57
    Content type: Research Published on:

    The Retraction Note to this article has been published in Journal of Hematology & Oncology 2018 11:2

  27. The poor prognosis and the limited efficacy of targeted therapy in patients with triple-negative breast cancer (TNBC) have raised the need for alternative therapies. Recent studies have demonstrated that folat...

    Authors: De-Gang Song, Qunrui Ye, Mathilde Poussin, Jessica A. Chacon, Mariangela Figini and Daniel J. Powell Jr.
    Citation: Journal of Hematology & Oncology 2016 9:56
    Content type: Research Published on:

  28. Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well ...

    Authors: Yucai Wang, Larysa Sanchez, David S. Siegel and Michael L. Wang
    Citation: Journal of Hematology & Oncology 2016 9:55
    Content type: Review Published on:

  29. The purpose of this study was to better understand the efficacy and safety of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma(R/RMM).

    Authors: Liping Liu, Ningning Zhao, Wenjun Xu, Zhixin Sheng and Lida Wang
    Citation: Journal of Hematology & Oncology 2016 9:54
    Content type: Letter to the Editor Published on:

  30. Previous studies have demonstrated that regulatory T cells (Tregs) play a protective role in the pathogenesis of chronic graft-versus-host disease (cGVHD). Tregs constitutively express the gene of the transcri...

    Authors: Gilles Fransolet, Grégory Ehx, Joan Somja, Loïc Delens, Muriel Hannon, Joséphine Muller, Sophie Dubois, Pierre Drion, Jo Caers, Stéphanie Humblet-Baron, Philippe Delvenne, Yves Beguin, Giuseppina Conteduca and Frédéric Baron
    Citation: Journal of Hematology & Oncology 2016 9:53
    Content type: Research Published on:

  32. Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death ...

    Authors: Larysa Sanchez, Yucai Wang, David S. Siegel and Michael L. Wang
    Citation: Journal of Hematology & Oncology 2016 9:51
    Content type: Review Published on:

  33. Venetoclax, a small molecule BH3 mimetic which inhibits the anti-apoptotic protein Bcl-2, and idasanutlin, a selective MDM2 antagonist, have both shown activity as single-agent treatments in pre-clinical and c...

    Authors: Christian Lehmann, Thomas Friess, Fabian Birzele, Anna Kiialainen and Markus Dangl
    Citation: Journal of Hematology & Oncology 2016 9:50
    Content type: Research Published on:

  35. Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. G...

    Authors: Georgia J. B. McCaughan, Michael J. Fulham, Annabelle Mahar, Judy Soper, Angela M. Hong, Paul D. Stalley, Martin H. N. Tattersall and Vivek A. Bhadri
    Citation: Journal of Hematology & Oncology 2016 9:48
    Content type: Case report Published on:

  36. Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death prote...

    Authors: Weijie Ma, Barbara M. Gilligan, Jianda Yuan and Tianhong Li
    Citation: Journal of Hematology & Oncology 2016 9:47
    Content type: Review Published on:

  38. Somatic calreticulin (CALR), Janus kinase 2 (JAK2), and thrombopoietin receptor (MPL) mutations essentially show mutual exclusion in myeloproliferative neoplasms (MPN), suggesting that they activate common onc...

    Authors: Lijuan Han, Claudia Schubert, Johanna Köhler, Mirle Schemionek, Susanne Isfort, Tim H. Brümmendorf, Steffen Koschmieder and Nicolas Chatain
    Citation: Journal of Hematology & Oncology 2016 9:45
    Content type: Research Published on:

  39. Long noncoding RNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) has been characterized as a critical factor in all-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) cel...

    Authors: Shuyong Wei, Ming Zhao, Xiaoling Wang, Yizhen Li and Kankan Wang
    Citation: Journal of Hematology & Oncology 2016 9:44
    Content type: Rapid communication Published on:

  40. In vitro culture of hematopoietic stem and progenitor cells (HPCs) is supported by a suitable cellular microenvironment, such as mesenchymal stromal cells (MSCs)—but MSCs are heterogeneous and poorly defined. ...

    Authors: Theresa Vasko, Joana Frobel, Richard Lubberich, Tamme W. Goecke and Wolfgang Wagner
    Citation: Journal of Hematology & Oncology 2016 9:43
    Content type: Letter to the Editor Published on:

  41. In tumor microenvironment, a continuous cross-talk between cancer cells and other cellular components is required to sustain tumor progression. Accumulating evidence suggests that exosomes, a novel way of cell...

    Authors: Xiaoxia Li, Shihua Wang, Rongjia Zhu, Hongling Li, Qin Han and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2016 9:42
    Content type: Research Published on:

  42. Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but optimal treatment is unclear. Therefore, we analyzed the efficacy of l-asparaginase-based regimens for ANKL p...

    Authors: Ki Sun Jung, Su-Hee Cho, Seok Jin Kim, Young Hyeh Ko, Eun-Suk Kang and Won Seog Kim
    Citation: Journal of Hematology & Oncology 2016 9:41
    Content type: Letter to the Editor Published on:

  43. Frequency relapses are common in Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) following tyrosine kinase inhibitors (TKIs). CDKN2A/B is believed to contribute to this chemot...

    Authors: Na Xu, Yu-ling Li, Xuan Li, Xuan Zhou, Rui Cao, Huan Li, Lin Li, Zi-yuan Lu, Ji-xian Huang, Zhi-ping Fan, Fen Huang, Hong-sheng Zhou, Song Zhang, Zhi Liu, Hong-qian Zhu, Qi-fa Liu…
    Citation: Journal of Hematology & Oncology 2016 9:40
    Content type: Research Published on:

  44. The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to be categorised and treated as e...

    Authors: Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva-Maria Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova…
    Citation: Journal of Hematology & Oncology 2016 9:39
    Content type: Research Published on:

  45. There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall su...

    Authors: Cinzia Pellegrini, Anna Dodero, Annalisa Chiappella, Federico Monaco, Debora Degl’Innocenti, Flavia Salvi, Umberto Vitolo, Lisa Argnani, Paolo Corradini and Pier Luigi Zinzani
    Citation: Journal of Hematology & Oncology 2016 9:38
    Content type: Research Published on:

  46. Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. Wit...

    Authors: Yaping Zhang, Wei Xu, Hong Liu and Jianyong Li
    Citation: Journal of Hematology & Oncology 2016 9:37
    Content type: Review Published on:

  47. The constitutive hyper-activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathways has frequently been associated with acute myeloid leukem...

    Authors: Yanan Gao, Juan Gao, Minghao Li, Yawei Zheng, Yajie Wang, Hongyan Zhang, Weili Wang, Yajing Chu, Xiaomin Wang, Mingjiang Xu, Tao Cheng, Zhenyu Ju and Weiping Yuan
    Citation: Journal of Hematology & Oncology 2016 9:36
    Content type: Research Published on:

  48. In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than one donor. A key issue in the haplo-SCT setting is the search for the best donor, because donor selection can signif...

    Authors: Ying-Jun Chang, Leo Luznik, Ephraim J. Fuchs and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2016 9:35
    Content type: Review Published on:

  50. Recent studies indicate that angiogenesis is important in the pathogenesis of acute myeloid leukemias (AMLs). Among the various AMLs, the bone marrow angiogenetic response is particularly pronounced in acute p...

    Authors: Ernestina Saulle, Alessia Petronelli, Elvira Pelosi, Elena Coppotelli, Luca Pasquini, Ramona Ilari, Francesco Lo-Coco and Ugo Testa
    Citation: Journal of Hematology & Oncology 2016 9:33
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us